Cavinton forte: instructions for using the medicine, structure, Contraindications
Active material: Vinpocetine
When ATH: N06BX18
CCF: Preparation, improves blood circulation and metabolism of the brain
ICD-10 codes (testimony): F01, F07, F07.2, G45, G45.0, G93.4, H34, H35.0, H35.3, H81, H81.0, H93.0, I61, I63, I67.2, I67.4, I69, S06, T90
When CSF: 02.15
Manufacturer: GEDEON RICHTER Ltd. (Hungary)
Cavinton forte: dosage form, composition and packaging
Pills round, flat, white or nearly white, chamfered, with an inscription “10 mg” on one side and with Valium – another.
| 1 tab. | |
| Vinpocetine | 10 mg |
Excipients: magnesium stearate, colloidal silicon dioxide, talc, lactose monohydrate, corn starch.
15 PC. – blisters (2) – packs cardboard.
15 PC. – blisters (6) – packs cardboard.
Cavinton forte: pharmachologic effect
Preparation, improving a cerebral circulation. It improves metabolism of the brain, increasing the consumption of glucose and oxygen to the tissues of the brain. It increases resistance of neurons to hypoxia, enhancing the transport of glucose to the brain through the BBB; transforms the process of disintegration of glucose energy to a more economical way of aerobic; Are selectively blokiruet 2+-dependent phosphodiesterase (PDE ); It increases the levels of cAMP and cGMP brain. Increasing the concentration of ATP and the ratio of ATP / AMP in brain tissue; exchange enhances noradrenaline and serotonin brain; It stimulates the ascending branch of the noradrenergic system, It has an antioxidant effect.
Reduces the aggregation of platelets and increased blood viscosity; It increases the ability of red blood cells deforming and blocks adenosine utilization by erythrocytes; enhances oxygen release erythrocytes. It enhances the neuroprotective effect of adenosine.
Increases cerebral blood flow; reduces the resistance of cerebral vessels without significant changes in the systemic circulation figures (FROM, minute volume, Heart Rate, PR). Not only has no effect “steal”, but also enhances blood supply primarily in ischemic areas of the brain with low perfusion.
Cavinton forte: pharmacokinetics
Absorption
After ingestion is rapidly absorbed. Cmax plasma levels achieved after 1 h after administration. Absorption occurs mainly in the proximal gastrointestinal tract. During the passage through the intestinal wall is not subjected to metabolism. Cmax tissue observed after 2-4 hours after ingestion. Bioavailability is 7%.
Distribution
In repeated oral dose 5 mg 10 mg kinetics is linear.
Associated with the plasma protein by 66%. It penetrates through the placental barrier.
Metabolism and excretion
Clearance 66.7 l / h higher than the plasma volume of the liver (50 l /), which indicates extrahepatic metabolism.
T1/2 is 4.83 ± 1.29ch. Excreted in the urine and faeces in the ratio 3:2.
Cavinton forte: testimony
- To reduce the severity of neurological and psychiatric symptoms in various forms of insufficiency of cerebral circulation (incl. state after ischemic stroke, restorative stage of hemorrhagic stroke, the effects of a stroke, tranzitornaya ishemicheskaya attack, sosudistaya dementia, vertebrobasilar insufficiency, cerebral atherosclerosis, posttraumatic and hypertensive encephalopathy);
- chronic vascular eye diseases (lesions of the choroid and retina);
- in otorhinolaryngological practice (for the treatment of hearing loss perceptual type, Meniere's disease, idiopathic tinnitus).
Cavinton forte: dosing regimen
The duration of treatment and the dose determined individually.
The average daily dose is 15-30 mg (by 5-10 mg 3 times / day). The initial daily dose is 15 mg. The maximum daily dose – 30 mg.
The therapeutic effect is about a week from the beginning of the drug. To achieve the full therapeutic effect requires three months.
At renal dysfunction and liver correction dosing regime is not required, no cumulation allows for long-term treatment.
Cavinton forte: side effects
Cardio-vascular system: ECG changes (ST depression, QT prolongation); tachycardia, arrythmia (However, a causal relationship has not been proven unnecessarily. in natural populations of these symptoms occur with the same frequency); labile blood pressure, feeling the tides.
CNS: sleep disorders (insomnia, hypersomnia), dizziness, headache, generalized weakness (These symptoms may be manifestations of the underlying disease), increased perspiration.
From the digestive system: dry mouth, nausea, heartburn.
Allergic reactions: skin rash, hives.
Cavinton forte: Contraindications
- acute phase of hemorrhagic stroke;
- severe form of coronary artery disease;
- severe arrhythmias;
- pregnancy;
- lactation (breast-feeding);
- Children up to age 18 years;
- hypersensitivity to vinpocetine or other components of the drug.
Cavinton forte: Pregnancy and lactation
Kavinton® Forte is contraindicated during pregnancy, tk. vinpocetine crosses the placental barrier. Thus its concentration in the placenta and fetal blood following, than in the blood of pregnant. When taken in high doses may develop placental bleeding and spontaneous abortion, probably due to increased placental blood supply.
During 1 h breast milk allocated 0.25% the dose of the drug. If necessary, use during lactation should stop breastfeeding.
Cavinton forte: Special instructions
The presence of the syndrome of prolonged QT interval, and concomitant use of drugs, causing QT prolongation, It requires periodic monitoring of ECG.
In the case of lactose intolerance should be considered, one tablet of the drug Cavinton® Forte contains 83 mg lactose monohydrate.
Use in Pediatrics
The drug Cavinton® Forte should not be given children and adolescents under the age of 18 years due to lack of data on its use in these patients.
Effects on ability to drive vehicles and management mechanisms
Data on the impact of the drug Cavinton® Forte on the ability to drive a car there and working mechanisms.
Cavinton forte: overdose
Currently, data on drug overdose Cavinton® Forte limited.
Treatment: gastric lavage, administration of activated charcoal, simptomaticheskaya therapy.
Cavinton forte: drug interaction
There has been no interaction during concomitant use of beta-blockers (xloranolol, pindolol), klopamydom, glibenclamide, digoksinom, acenocoumarol and hydrochlorothiazide, imipramine.
Simultaneous use of the drug methyldopa Kavinton® Forte and sometimes caused a strengthening of the hypotensive effect, therefore, the application of such a combination requires regular monitoring of blood pressure.
Despite the lack of data, supporting interoperability, advised to exercise caution while appointing Kavintona® Forte with centrally acting agents, antiarrhythmic drugs, and anticoagulants.
Cavinton forte: terms of dispensing from pharmacies
The drug is released under the prescription.
Cavinton forte: terms and conditions of storage
List B. The drug should be stored in the dark, inaccessible to children at temperature from 15 ° to 30 ° C. Shelf life – 5 years.
